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Abstract
The severity of disease of Covid‐19 is highly variable, ranging from asymptomatic to
critical respiratory disease and death. Potential cross‐reactive immune responses
between SARS‐CoV‐2 and endemic coronavirus (eCoV) may hypothetically con-
tribute to this variability. We herein studied if eCoV nucleoprotein (N)‐specific
antibodies in the sera of patients with mild or severe Covid‐19 are associated with
Covid‐19 severity. There were comparable levels of eCoV N‐specific antibodies
early and during the first month of infection in Covid‐19 patients with mild and
severe symptoms, and healthy SARS‐CoV‐2‐negative subjects. These results war-
rant further studies to investigate the potential role of eCoV‐specific antibodies in
immunity to SARS‐CoV‐2 infection.
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1 | INTRODUCTION
Among the large family of coronaviruses (subfamily Orthocor-
onavirinae in the family of Coronaviridae of the order Nidovirales),
seven are known to infect humans. Four endemic coronaviruses
(eCoVs), the species HCoV‐NL63 and HCoV‐229E within the genus
Alphacoronavirus and the species HCoV‐OC43 and HCoV‐HKU1
within the genus Betacoronavirus, spread seasonally and cause the
common cold.1 Three additional betacoronaviruses, namely SARS‐
CoV, MERS‐CoV, and SARS‐CoV‐2, can cause severe respiratory
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syndromes in humans.2 A hallmark of Covid‐19, the disease caused
by SARS‐CoV‐2 infection, is the great variability in the severity of
disease, ranging from asymptomatic to critical respiratory disease
and death. Potential cross‐reactive immune responses between
SARS‐CoV‐2 and eCoVs may hypothetically contribute to this
variability, either by affording cross‐protection or by being detri-
mental via antibody‐dependent enhancement.
During Covid‐19, antibody responses mainly target the spike (S)
glycoprotein and the nucleoprotein (N).3 Antibodies against the
receptor‐binding domain (RBD) of the S protein possess potent virus‐
neutralizing capacity, whereas antibodies against the internal struc-
ture N protein do not. Nevertheless, N‐specific antibodies are in-
dicative of antiviral immunity, exemplified in a recent epidemiological
study, which demonstrated that healthcare workers with
N‐antibodies had a much lower risk of testing polymerase chain re-
action (PCR)‐positive for SARS‐CoV‐2 than those without, and that
the incidence of PCR‐positive results fell with increasing N‐antibody
titers.4 Several studies have demonstrated the presence of T‐cell and
antibody cross‐reactivity between several epitopes of SARS‐CoV‐2
and the eCoVs.5–7 Although eCoV S‐specific antibody responses in
Covid‐19 patients have been studied,8 there is a dearth of informa-
tion on eCoV N‐specific antibody responses in Covid‐19 patients
with varying severity of the disease. Importantly, a recent report that
studied medical records found that though recent eCoV infections
were not associated with lower rates of SARS‐CoV‐2 infection, they
were associated with reduced severity of Covid‐19.9
Herein, we explored eCoV N‐specific antibodies in the sera of
Covid‐19 patients with mild or severe symptoms and healthy SARS‐
CoV‐2‐negative individuals by an assessment of specific antibodies
to N‐protein of the four eCoVs and SARS‐CoV‐2. Our results showed
that comparable levels of eCoV N‐specific antibodies were observed
in patients with mild and severe Covid‐19. These results enhance our
understanding of the impact of human antibody responses to eCoVs
on the severity of Covid‐19.
2 | MATERIALS AND METHODS
2.1 | Patients and sample collection
A cohort of 43 patients (70% female; age range, 23–84 years) with
PCR‐confirmed SARS‐CoV‐2 infection with mild (n = 21) or severe/
critical (n = 22) symptoms of Covid‐19 were recruited between
February 25 and November 23, 2020, at the Department of In-
fectious Diseases, Sahlgrenska University Hospital, Gothenburg,
Sweden. The study protocol was approved by the Swedish Ethical
Review Authority (Registration Number: 2020–01771) and patients
were included in the study after written informed consent. Severe/
critical disease was defined as the requirement of intensive care with
mechanical ventilation, and mild disease as not requiring supple-
mentary oxygen or hospitalization. Medical conditions, defined by
the Centers for Disease Control and Prevention, USA, as having a
significant association with risk of severe Covid‐19 illness (e.g.,
cancer, cerebrovascular disease, chronic kidney disease, chronic
obstructive pulmonary disease, heart conditions, im-
munocompromised state, obesity, pregnancy, and diabetes mellitus
type 1 and 210), were collected from the subjects' medical records.
Information on the smoking status of the study participants was
incomplete and therefore not included. Serum samples retrieved
from healthy volunteers who tested negative for SARS‐CoV‐2 with
PCR (n = 27; 56% female; age range, 20–79 years) between January
29 and September 23, 2020, were included as controls. In the study
that compared antibody levels between the mild and severe Covid‐
19 patient groups, acute serum samples collected within 10 days
after debut of symptoms (mean four days post symptom onset for
patients with mild disease and eight days for patients with severe
disease) were used. For the analysis of longitudinal antibody devel-
opment, subjects were included for which two or more samples from
the first 30 days after symptom debut were available (n = 23).
2.2 | Antibody detection
Antibodies specific for HCoV‐NL63, HCoV‐229E, HCoV‐HKU1, and
HCoV‐OC43 were analyzed using the C‐terminal part of the N‐
protein as antigen in enzyme‐linked immunosorbent antibodies
(ELISAs) as described elsewhere.1 SARS‐CoV‐2‐specific total anti-
body was analyzed using the SARS‐CoV‐2 N‐protein double re-
cognition ELISA INgezim test as previously described.11 This assay is
based on the use of the same protein (in this case, the N protein) as
the target antigen and detection molecule, using the principle that
antibodies possess multiple antigen‐binding regions (2 for IgG, 4 for
IgA, and 10 for IgM), allowing their simultaneous binding to both the
target and detection antigen. Double recognition tests have the ad-
vantage that they detect all antigen‐specific antibodies, regardless of
their class (IgA, IgG, or IgM).
2.3 | Statistical analysis
Differences between the groups were analyzed using analysis of
variance with Tukey's multiple comparisons test for eCoV antibodies,
and Fisher's exact test for SARS‐CoV‐2 antibodies for which there is
a cut‐off for positivity. Correlations were analyzed using Pearson.
p < 0.05 was considered statistically significant.
3 | RESULTS AND DISCUSSION
Due to the ubiquitous nature of the eCoV, all adults are considered
to be exposed to eCoVs, though eCoV‐specific antibody levels have
been shown to rapidly wane and reinfections are common.1 SARS‐
CoV‐2‐specific antibodies are detectable a median of 11 days (in-
terquartile range, 7–14 days) post symptom onset,3 although with a
considerable interpatient variability and differences in results de-
pending on the assay used.
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First, we investigated if magnitudes of antibodies against
eCoVs in the early serum samples (collected maximum 10 days
post symptom onset) in SARS‐CoV‐2‐infected patients with mild
or severe Covid‐19 are correlated with the severity of Covid‐19
developed, using N‐specific antibody ELISAs. No statistically
significant differences in the levels of N‐specific antibodies
against any of the four eCoVs were observed in Covid‐19 pa-
tients with mild disease, severe disease, or healthy controls
(Figure 1A). Although SARS‐CoV‐2 N‐specific antibodies were
higher in patients with severe compared to mild symptoms, this
difference is likely partly due to the longer duration of disease in
the patients with severe symptoms. At least one pre‐existing
comorbidity known to increase the risk of severe Covid‐19 was
present in a higher proportion of patients with severe disease
(27%) compared with mild disease (14%), which could bias these
results. However, when all subjects with comorbidities (n = 9)
were excluded, conclusions based on statistical significance le-
vels remain unchanged.
There were no statistically significant correlations between the
magnitudes of SARS‐CoV‐2 N‐specific antibodies and any of the
eCoV N‐specific antibodies (data not shown). This confirms that
SARS‐CoV‐2 N‐specific antibodies have no substantial cross‐
reactivity with eCoV epitopes in the C‐terminal part of the N‐protein
used as antigen in the present study. Our finding on the lack of
inverse correlation between eCoV N‐specific antibodies and disease
severity is in line with, and extends, a previous report on the lack of
cross‐reactive neutralizing activity against SARS‐CoV‐2 in the pre‐
pandemic sera of individuals with prior PCR‐confirmed eCoV
infection.12
As the samples in patients with mild disease were collected
mean 4 days earlier than in patients with severe disease, the anti-
body levels in patients with mild disease could be misleadingly low.
To examine this, longitudinal samples retrieved from the same pa-
tients during the first month of infection were analyzed. As expected,
SARS‐CoV‐2 antibody levels increased significantly over time (r = 0.4;
p = 0.003; Figure 1B). In contrast, N‐specific antibody levels to
F IGURE 1 (A) Magnitudes (mean ± SD where relevant) of N‐specific antibodies against SARS‐CoV‐2 and the endemic coronaviruses.
Samples collected within 10 days of symptom onset in Covid‐19 patients with mild symptoms (n = 21, blue) or severe/critical symptoms (n = 22,
red), and SARS‐CoV‐2‐negative controls (n = 27, green). (B) Serial samples collected during the first 30 days since symptom onset in Covid‐19
patients with mild symptoms (n = 5, blue) or severe/critical symptoms (n = 18, red). Dotted line in (A) indicates assay cut‐off for positivity for
SARS‐CoV‐2 antibodies. ****p < 0.0001, *p < 0.05, ns: not significant
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HCoV‐NL63, HCoV‐229E, and HCoV‐OC43 did not increase over
time, and HCoV‐HKU1 antibodies even showed a trend toward de-
creasing over time (r = −0.32; p = 0.02). Thus, the lack of difference
between eCoV‐specific antibodies in those patients that are severely
ill and those that show only mild symptoms is unlikely influenced by
the 4‐day difference in sampling timing.
The eCoV N‐specific antibody levels detected in the samples prob-
ably reflect pre‐existing serum antibodies, which do not appear to have
been boosted by the SARS‐CoV‐2 infection, supported by the fact that
these serum antibody levels remain stable or even slightly decrease
during the first month and do not increase in parallel to the SARS‐CoV‐2
antibodies (Figure 1B). Notwithstanding, the possibility that memory
responses to eCoV N‐protein elicited by prior eCoV infections were very
rapidly boosted by SARS‐CoV‐2 infection cannot be entirely ruled out.
Additionally, it is conceivable that memory B‐cells specific for other eCoV
proteins, such as the S2 subunit,6,7 with more cross‐reactivity to SARS‐
CoV‐2 counterparts, could be induced by SARS‐CoV‐2 infection.
In conclusion, we report comparable levels of eCoV N‐specific an-
tibodies early and during the first month after the onset of symptoms in
Covid‐19 patients with mild and severe symptoms. These results warrant
further studies to investigate the potential role of eCoV‐specific anti-
bodies in immunity to SARS‐CoV‐2 infection.
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